News >

Vorasidenib, Ivosidenib Show Encouraging Activity in IDH1-Mutant Low-Grade Glioma

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 25, 2019

Ingo K. Mellinghoff, MD, acting co-chair and vice chair for Research in the Department of Neurology, chief of Brain Tumor Service, and Evnin Family Chair in Neuro-Oncology of Memorial Sloan Kettering Cancer Center

Ingo K. Mellinghoff, MD

Single-agent vorasidenib or ivosidenib (Tibsovo) led to brain penetrance and 2-hydroxyglutarate (2-HG) suppression in patients with low-grade glioma who harbor IDH1 mutations, according to updated data from an ongoing, 2-cohort, perioperative study (NCT03343197) that were presented at the 2019 Society for Neuro-Oncology Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication